- Alzheimer's disease
- Bone research
- Brain and CNS
Cancer and inflammation
- Bcl-1 cyclin D1
- COX-1 COX-2
- Fatty acid synthase
- Hepatocyte growth factor
- Intelectin-1 Omentin-1
- Napsin A
- Poly ADP-ribose
- Stem cell factor
- Cell adhesion and ECM
- Environmental hazards
- Epigenetic antibodies
- Metabolic diseases
- mTOR signaling
- Signal transduction
- Stem cell research antibodies
- Virus research
- Miscellaneous research areas
The human cyclin-dependent kinase inhibitor 2A (CDKN2A) gene generates several transcript variants that differ in their first exons. At least three alternatively spliced variants encoding distinct proteins have been reported. One of these, cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4) or p16INK4a, interacts with, and sequesters, the E3 ubiquitin-protein ligase MDM2, a protein responsible for the degradation of p53. Thus, p16INK4a functions as a tumor suppressor in a variety of cells. Mutations in the CDKN2A gene are often found in many tumors. p16INK4a is also suggested to play a role in controlling cell proliferation and apoptosis during mammary gland development.
This product is an affinity-purified IgG antibody that recognizes human p16INK4a protein. The antibody was raised in mouse using recombinant p16-INK4a and can be used for Western blot (WB) detection, immunohistochemical (IHC) detection, or immunoprecipitation (IP) of human p16INK4a protein.
- Target Name: Human p16INK4a protein
- Antigen: Human p16INK4a recombinant protein
- Target Entrez Gene ID: 1029
Recommended antibody concentration (the optimal concentration should be determined empirically):
- Western blot: 1 µg/ml
- Immunohistochemical techniques: 5 µg/ml
- Immunoprecipitation: 2 µg/ml
Lyophilized: stable for 5 years at 2–8°C. In solution: stable for 2 years at –20°C.
Lyophilized from an antibody solution containing 1% BSA in PBS and 0.05% NaN3. To use, reconstitute in 1.0 ml H2O (final concentration 100 µg/ml).
Cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4); cyclin-dependent kinase inhibitor 2A, CDKN2A, cyclin-dependent kinase 4 inhibitor A, CDK4 inhibitor p16-INK4, cell cycle negative regulator beta, multiple tumor suppressor 1, MTS-1, ARF, MLM, p14, p16, p19, CMM2, INK4, INK4A, TP16, CDK4I, CDKN2, p14-ARF, p19-ARF, and p16-INK4.
Additional product information
Please see the product's Certificate of Analysis for information about storage conditions, product components, and technical specifications. Please see the Kit Components List to determine kit components. Certificates of Analysis and Kit Components Lists are located under the Documents tab.
Takara Bio USA, Inc.
United States/Canada: +1.800.662.2566 • Asia Pacific: +1.650.919.7300 • Europe: +33.(0)1.3904.6880 • Japan: +81.(0)77.565.6999
FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES. © 2018 Takara Bio Inc. All Rights Reserved. All trademarks are the property of Takara Bio Inc. or its affiliate(s) in the U.S. and/or other countries or their respective owners. Certain trademarks may not be registered in all jurisdictions. Additional product, intellectual property, and restricted use information is available at takarabio.com.